{"id":42603,"date":"2023-04-30T17:49:47","date_gmt":"2023-04-30T21:49:47","guid":{"rendered":"https:\/\/www.sisinternational.com\/?page_id=42603"},"modified":"2026-05-05T17:01:22","modified_gmt":"2026-05-05T21:01:22","slug":"investigacion-de-mercado-de-diagnostico-clinico","status":"publish","type":"page","link":"https:\/\/www.sisinternational.com\/es\/soluciones\/investigacion-de-mercado-biotecnologico-y-farmaceutico-de-atencion-medica\/investigacion-de-mercado-de-diagnostico-clinico\/","title":{"rendered":"Clinical Diagnostics Market Research | SIS International"},"content":{"rendered":"
\n

Investigaci\u00f3n de mercado de diagn\u00f3stico cl\u00ednico<\/a><\/h1>\n
\"Investigaci\u00f3n<\/figure>\n<\/p>\n

Clinical Diagnostics identifies the presence or absence of a disease or medical condition. Medical professionals do Clinical Diagnostics through various tests and procedures. The diagnostic process involves a series of steps. For example, the process may include medical history, physical examination, and laboratory tests. They may also consist of imaging studies and other diagnostic<\/a> procedures. Medical professionals use all these methods to make a definitive diagnosis. Or, they may use them to rule out potential conditions.<\/p>\n

Otra funci\u00f3n del Diagn\u00f3stico Cl\u00ednico es identificar y gestionar diversas condiciones de salud. Contraen dolencias comunes (por ejemplo, la gripe). Tambi\u00e9n identifican enfermedades m\u00e1s complejas y cr\u00f3nicas como el c\u00e1ncer y la diabetes. Adem\u00e1s, los dise\u00f1adores de pruebas y procedimientos tienen mucho en juego con sus productos. Se han asegurado de poder proporcionar resultados precisos y confiables. Estos resultados deber\u00edan guiar las decisiones de tratamiento y mejorar los resultados de los pacientes.<\/p>\n

Algunos ejemplos de pruebas y procedimientos de diagn\u00f3stico cl\u00ednico incluyen an\u00e1lisis de sangre y orina. Los estudios de im\u00e1genes, como las radiograf\u00edas y las resonancias magn\u00e9ticas, tambi\u00e9n son diagn\u00f3sticos. Tambi\u00e9n lo son las biopsias y las pruebas gen\u00e9ticas. Otro punto clave es que las pruebas y procedimientos espec\u00edficos dependen de la condici\u00f3n sospechada. Tambi\u00e9n se relacionan con los s\u00edntomas y el historial m\u00e9dico del paciente.<\/p>\n

\u00bfPor qu\u00e9 son importantes los diagn\u00f3sticos cl\u00ednicos?<\/h2>\n

El diagn\u00f3stico cl\u00ednico es esencial por varias razones, incluida la detecci\u00f3n temprana y la prevenci\u00f3n. De hecho, el diagn\u00f3stico cl\u00ednico permite la detecci\u00f3n temprana de enfermedades y condiciones m\u00e9dicas. La detecci\u00f3n temprana puede ayudar a prevenir el desarrollo de complicaciones m\u00e1s graves. Adem\u00e1s, el diagn\u00f3stico y el tratamiento tempranos son cruciales para el c\u00e1ncer, las enfermedades cardiovasculares y la diabetes. Puede mejorar los resultados y reducir las tasas de mortalidad.<\/p>\n

Los diagn\u00f3sticos cl\u00ednicos proporcionan informaci\u00f3n precisa y confiable sobre la condici\u00f3n de un paciente. Esta informaci\u00f3n es esencial para tomar decisiones de tratamiento informadas. Sin mencionar que sin un diagn\u00f3stico adecuado, los pacientes pueden recibir un tratamiento inadecuado e inadecuado. Peor a\u00fan, el tratamiento puede ser perjudicial o poner en peligro la vida.<\/p>\n

Los diagn\u00f3sticos cl\u00ednicos permiten monitorear la respuesta de un paciente al tratamiento a lo largo del tiempo. Los proveedores de atenci\u00f3n m\u00e9dica pueden utilizar esta informaci\u00f3n para ajustar los planes de tratamiento. Con \u00e9l, tambi\u00e9n pueden garantizar que los pacientes reciban la mejor atenci\u00f3n posible.<\/p>\n

El diagn\u00f3stico cl\u00ednico desempe\u00f1a un papel fundamental en la investigaci\u00f3n y el desarrollo m\u00e9dicos. Los profesionales m\u00e9dicos los utilizan para probar nuevas terapias y medicamentos. Tambi\u00e9n pueden identificar nuevos biomarcadores y objetivos para el tratamiento de enfermedades.<\/p>\n

Para aclarar, el diagn\u00f3stico cl\u00ednico es esencial para mejorar los resultados de los pacientes y avanzar en el conocimiento m\u00e9dico. Permiten el diagn\u00f3stico preciso de diversas enfermedades y afecciones. Tambi\u00e9n permiten un tratamiento eficaz, lo que conduce a mejores resultados de salud del paciente.<\/p>\n<\/div>\n

Clinical Diagnostics Estudios de mercado<\/a>: How Leaders Build Defensible Launch Strategy<\/h1>\n

Clinical diagnostics market research now decides which assays reach reimbursement and which stall in pilot accounts. The diagnostics buyer is no longer a single pathologist. It is a procurement committee balancing reagent cost, instrument footprint, LIS integration, and payer coverage decisions. Winning teams treat that complexity as an addressable variable, not a barrier.<\/p>\n

The opportunity is significant. Molecular diagnostics, companion diagnostics (CDx), point-of-care (POC) platforms, and laboratory-developed tests (LDTs) are converging into a single competitive arena. The firms gaining share are the ones running disciplined primary research against the actual decision unit: lab directors, KOL pathologists, payer medical directors, and health system supply chain leads.<\/p>\n

What Sophisticated Clinical Diagnostics Market Research Now Measures<\/h2>\n

The conventional approach maps physician preference and stops there. The better approach maps the full reimbursement-to-utilization chain. That means quantifying CPT code coverage decisions, PAMA-driven price compression on the Clinical Laboratory Fee Schedule, and the gating effect of MolDX local coverage determinations on assay adoption.<\/p>\n

Three measurement layers separate strong diagnostics research from generic physician surveys. First, payer value story testing against medical policy criteria. Second, lab director willingness-to-validate scoring, which predicts adoption faster than physician intent. Third, KOL mapping that distinguishes guideline authors from prescribing volume leaders. The two rarely overlap.<\/p>\n

SIS International’s structured expert interviews with pathologists, oncologists, and reproductive health specialists in tier-one and tier-two Indian metros surfaced a pattern most secondary reports miss: in molecular diagnostics, ordering behavior follows turnaround time and send-out logistics more than analytical sensitivity, once a minimum performance bar is met.<\/span> That insight reframes commercial priorities for any oncology or NIPT entrant.<\/p>\n

Why Companion Diagnostics Demand a Different Research Design<\/h2>\n

Companion diagnostics sit inside a pharma launch. The research question is not “will physicians order this test.” It is “will the test keep pace with therapy uptake across reference labs, hospital labs, and decentralized POC settings.” Roche, Illumina, and Thermo Fisher build CDx commercial strategy on parallel-track studies that interview pharma alliance managers and lab medical directors in the same wave.<\/p>\n

Real-world evidence (RWE) generation runs alongside. Payers increasingly demand outcomes data tied to test-directed therapy before issuing positive coverage. Research design that ignores this produces a value story the medical policy team will reject in the first review cycle.<\/p>\n

Point-of-Care and Decentralized Testing: A Distinct Decision Unit<\/h2>\n

POC molecular platforms from Cepheid, BioFire, and Abbott shifted procurement authority away from central lab directors toward emergency department leadership, urgent care operators, and retail clinic chains. Each buyer applies different criteria. ED leaders weigh door-to-disposition time. Retail operators weigh CLIA-waived status and cartridge cost per test. Central labs weigh menu breadth and middleware integration.<\/p>\n

Research that treats POC as one segment loses precision. The leading sponsors run segmented quantitative work with separate sample frames per care setting, then triangulate against installed base analytics from GPO contract data.<\/p>\n

Geographic Nuance Drives Forecast Accuracy<\/h2>\n

Diagnostics adoption curves diverge sharply across markets. India’s molecular diagnostics market grows through standalone reference labs and oncology-focused chains. Brazil’s growth concentrates in private hospital networks and SUS tender cycles. Germany’s path runs through statutory health insurance EBM coding decisions. China’s NMPA pathway and volume-based procurement rewrite unit economics on entry.<\/p>\n

Across SIS International Research engagements in Brazilian healthcare, mixed-methodology designs combining hospital procurement interviews with quantitative physician surveys have consistently produced forecast variance under fifteen percent against actual two-year uptake, where single-method secondary forecasts have drifted further.<\/span> The discipline is straightforward: pair installed base reality with stated intent, then weight by reimbursement gating.<\/p>\n

The SIS Diagnostics Decision-Unit Framework<\/h2>\n

For pillar planning, the framework below organizes primary research scope across the four buyers that determine commercial outcome.<\/p>\n

\n\n\n\n\n\n\n\n\n
Decision Unit<\/th>\nPrimary Lever<\/th>\nM\u00e9todo de investigaci\u00f3n<\/th>\n<\/tr>\n<\/thead>\n
Lab Director \/ Pathologist<\/td>\nValidation burden, menu fit<\/td>\nB2B expert interviews, willingness-to-validate scoring<\/td>\n<\/tr>\n
Ordering Physician (KOL + community)<\/td>\nClinical utility, guideline alignment<\/td>\nQuantitative survey, conjoint on test attributes<\/td>\n<\/tr>\n
Payer Medical Director<\/td>\nEvidence package, coverage policy<\/td>\nPayer value story testing, RWE gap analysis<\/td>\n<\/tr>\n
Health System Procurement \/ GPO<\/td>\nTotal cost, contract structure<\/td>\nProcurement interviews, TCO modeling<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/figure>\n

Source: SIS International Research<\/em><\/p>\n

What Separates Launch-Ready Research From Reference-Shelf Research<\/h2>\n

Three signals indicate research that will hold up in a launch readiness review. The sample frame names specific institution types and regions, not “US hospitals.” The instrument tests price points anchored to actual CPT reimbursement, not arbitrary willingness-to-pay scales. The output ties directly to medical affairs, market access, and commercial workstreams with named decisions assigned to each.<\/p>\n

SIS International’s proprietary research in clinical mobility and diagnostics adoption across US and UK hospital systems found that IT integration friction, specifically LIS and EMR middleware compatibility, was the single largest predictor of replacement-cycle losses for incumbent platforms.<\/span> Sponsors who quantified that variable in advance won net-new accounts at materially higher rates.<\/p>\n

Where the Market Is Moving<\/h2>\n

Liquid biopsy, multi-cancer early detection (MCED), AI-enabled digital pathology, and next-generation sequencing menu expansion are reshaping competitive boundaries. Guardant Health, Exact Sciences, GRAIL, and Natera each compete on a different combination of clinical evidence depth, payer coverage breadth, and channel access. Research that benchmarks them on a single axis will mislead the strategy team.<\/p>\n

The forward question for diagnostics leaders is not market size. It is which decision-unit configurations in which geographies will convert evidence into reimbursed volume fastest. Clinical diagnostics market research, designed around that question, becomes a launch asset rather than a deck.<\/p>\n

Key Questions<\/h2>\n
\"Investigaci\u00f3n<\/figure>\n

Senior diagnostics leaders engaging SIS most often ask how to size molecular diagnostics opportunity in emerging markets, how to structure payer evidence for a CDx launch, and how to segment POC buyers by care setting. Each requires a different primary research design and a different sample frame.<\/p>\n

Acerca de SIS Internacional<\/h2>\n

SIS Internacional<\/a> ofrece investigaci\u00f3n cuantitativa, cualitativa y estrat\u00e9gica. Proporcionamos datos, herramientas, estrategias, informes y conocimientos para la toma de decisiones. Tambi\u00e9n realizamos entrevistas, encuestas, grupos focales y otros m\u00e9todos y enfoques de investigaci\u00f3n de mercado. P\u00f3ngase en contacto con nosotros<\/a> para su pr\u00f3ximo proyecto de Investigaci\u00f3n de Mercado.<\/p>\n

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n<\/p>\n

\n

Related SIS Resources<\/h3>\n